Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HC Wainwright Analyst Says

Biogen (NASDAQ:BIIB) had its target price increased by HC Wainwright from $194.00 to $228.00 in a report released on Monday, MarketBeat reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 20.64% from the company’s current price.

A number of other equities analysts have also recently weighed in on BIIB. Oppenheimer upped their price target on shares of Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. HSBC restated a “reduce” rating and set a $143.00 target price (down from $144.00) on shares of Biogen in a research report on Wednesday, December 10th. UBS Group initiated coverage on shares of Biogen in a research report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price target for the company. Stifel Nicolaus boosted their price target on Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Biogen in a report on Tuesday, January 13th. Thirteen research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Biogen currently has an average rating of “Hold” and a consensus target price of $207.81.

Biogen Price Performance

Shares of BIIB opened at $188.99 on Monday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The stock’s 50 day moving average is $177.44 and its two-hundred day moving average is $157.89. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41. The firm has a market capitalization of $27.74 billion, a PE ratio of 21.45, a P/E/G ratio of 1.55 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the firm earned $3.44 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts anticipate that Biogen will post 15.83 earnings per share for the current year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC purchased a new position in Biogen in the 2nd quarter valued at about $25,000. WPG Advisers LLC raised its position in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the last quarter. Rothschild Investment LLC lifted its stake in shares of Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 88 shares during the period. Accredited Wealth Management LLC lifted its stake in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. Finally, Concord Wealth Partners boosted its position in Biogen by 100.0% during the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 114 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.